Anebulo Pharmaceuticals Inc   (ANEB)
Other Ticker:  
Price: $2.1150 $-0.11 -4.730%
Day's High: $2.2322 Week Perf: -1.63 %
Day's Low: $ 2.05 30 Day Perf: -24.19 %
Volume (M): 5 52 Wk High: $ 4.05
Volume (M$): $ 11 52 Wk Avg: $2.56
Open: $2.16 52 Wk Low: $1.62

 Market Capitalization (Millions $) 55
 Shares Outstanding (Millions) 26
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of novel inhalation therapies for the treatment of severe respiratory diseases. They aim to provide innovative solutions for patients suffering from conditions such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), and asthma.

The company utilizes advanced inhalation technologies to deliver their drug candidates directly to the lungs, maximizing the drug's effectiveness and reducing systemic side effects. They are committed to improving patient outcomes and quality of life by addressing the unmet needs in respiratory medicine.

Anebulo Pharmaceuticals Inc has a robust pipeline of promising drug candidates in various stages of development. They prioritize rigorous research and development practices, conducting clinical trials to demonstrate the safety and efficacy of their products. Additionally, the company collaborates with academic institutions and industry partners to leverage expertise and accelerate the development of their therapies.

Overall, Anebulo Pharmaceuticals Inc is dedicated to revolutionizing respiratory care by bringing innovative inhalation therapies to market and making a significant impact on the lives of patients with severe respiratory diseases.

   Company Address: 1017 Ranch Road 620 South Lakeway 78734 TX
   Company Phone Number: 598-0931   Stock Exchange / Ticker: NASDAQ ANEB


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Anebulo Pharmaceuticals Inc

Major Pharmaceutical Preparations Company Shows Improvement with Operating Shortfall Progress in Q3 20242.

Anebulo Pharmaceuticals Inc (Nasdaq: ANEB), a clinical-stage biopharmaceutical company, recently released its financial results for the three months ended March 31, 2024, along with other important updates. Despite investors not anticipating significant changes in the top-line during this reporting season, the company recorded an operating shortfall of $-1.664251 million, reflecting a deviation from typical industry standards. However, while some analysts remain optimistic about ANEB's growth potential due to its expanding business model, there are several factors that contribute to a bearish sentiment towards the stock.
Financial Struggles:
One of the major concerns for investors is the company's consistent financial struggles. ANEB's operating shortfall in the first quarter of 2024 improved slightly from the previous quarter, but it still amounted to a significant $-1.664251 million. This indicates that the company is struggling to generate sufficient revenue to cover its operating expenses.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Reports Operating Shortfall of $-2.76 Million in Recent Financial Report

The recent financial report from Anebulo Pharmaceuticals Inc has brought some positive news for the company and its investors. Despite facing a operating shortfall, the company has managed to significantly reduce its losses compared to the same period last year. This shows that the company is making progress in improving its financial performance and becoming more efficient in its operations.
One of the most encouraging signs in the report is the decrease in Returns, which has dropped to $-2.717 million from $-3.827 million in the previous quarter. This indicates that the company is managing its resources more effectively and is on track to improve its profitability in the future.
While the stock price of Anebulo Pharmaceuticals Inc has experienced a decline in the past 5 trading days and over the past year, it is important to note that the overall trend is positive. The company's financial performance is improving, and this should ultimately lead to an increase in shareholder value over time.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc. Faces Operational Challenges with Worsened Deficit and Lack of Revenue in Q4 2023

As an industry expert in the Major Pharmaceutical Preparations sector, it is my duty to analyze and interpret the financial results of companies within this field. Today, I will be delving into the fourth quarter numbers of Anebulo Pharmaceuticals Inc.
The first observation to note is the operating deficit of $-2.494389 million reported by Anebulo Pharmaceuticals Inc. for the April to June 30, 2023 reporting season. This is a worsened deficit compared to the fourth quarter of 2022, which stood at $-2.325484 million. What is concerning is that the company has yet to report any revenue during this period, leaving market participants questioning when the company will begin generating revenue.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc. Sees Alarming Contraction in Business Behavior, with Operating Deficit Widening to $2.86 Million in Q3 2023

In financial news, ANEB has reported an operating deficit of $-2.864041 million for the third quarter of the fiscal year 2023. As an emerging growth company in the Major Pharmaceutical Preparations sector, ANEB has not yet reported their respective revenue, but the comparison to their third quarter of 2022 is informative. During the third quarter of 2022, ANEB reported an operating deficit of $-1.879644 million, whereas in the current period, the deficit has widened significantly to $-2.864041 million.
ANEB also reported a net deficit of $-2.798 million, up from $-1.876 million during the same period a year ago. While it may be concerning to see the deficit expanding, it is important to note that ANEB is an emerging growth company. As such, they may be focusing on growth and expansion rather than profits at this stage.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com